Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?

Summary

Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyper-reactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.

Keywords

ADP receptors - antiplatelet agents - clinical trials - antiplatelet drugs - platelet pharmacology

^* The first authors Sibbing and Gross contributed equally to this work.

• References

• 1 Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial.. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Eur Heart J 1992; 13: 594-598.
• 2 Muller JE, Ludmer PL, Willich SN. et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75: 131-138.
• 3 Willich SN, Levy D, Rocco MB. et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987; 60: 801-806.
• 4 Pelter MM, Adams MG, Wung SF. et al. Peak time of occurrence of myocardial ischaemia in the coronary care unit. Am J Crit Care 1998; 07: 411-417.
• 5 Patel DJ, Knight CJ, Holdright DR. et al. Pathophysiology of transient myocardial ischaemia in acute coronary syndromes. Characterization by continuous ST-segment monitoring. Circulation 1997; 95: 1185-1192.
• 6 Itaya H, Takagi T, Sugi K. et al. Absence of circadian variation of acute coronary syndrome onset in chronic kidney disease patients. Cardiovasc Revasc Med 2011; 12: 362-366.
• 7 Mahmoud KD, Lennon RJ, Ting HH. et al. Circadian variation in coronary stent thrombosis. JACC Cardiovasc Interven 2011; 04: 183-190.
• 8 Mogabgab O, Giugliano RP, Sabatine MS. et al. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int 2012; 29: 1390-1396.
• 9 Mogabgab O, Wiviott SD, Cannon CP. et al. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther 2013; 18: 555-559.
• 10 Mogabgab O, Wiviott SD, Antman EM. et al. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol 2013; 36: 222-227.
• 11 Kanth R, Ittaman S, Rezkalla S. Circadian patterns of ST elevation myocardial infarction in the new millennium. Clin Med Res 2013; 11: 66-72.
• 12 Patton KK, Hellkamp AS, Lee KL. et al. Unexpected deviation in circadian variation of ventricular arrhythmias: the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 2014; 63: 2702-2708.
• 13 Ruwald MH, Moss AJ, Zareba W. et al. Circadian distribution of ventricular tachyarrhythmias and association with mortality in the MADIT-CRT trial. J Cardiovasc Electrophysiol 2015; 26: 291-299.
• 14 Tofler GH, Brezinski D, Schafer AI. et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-1518.
• 15 Jafri SM, VanRollins M, Ozawa T. et al. Circadian variation in platelet function in healthy volunteers. Am J Cardiol 1992; 69: 951-954.
• 16 Dalby MC, Davidson SJ, Burman JF. et al. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. Platelets 2000; 11: 320-324.
• 17 Sawada M, Kishi Y, Numano F. et al. Smokers lack morning increase in platelet sensitivity to nitric oxide. J Cardiovasc Pharmacol 2002; 40: 571-576.
• 18 Scheer FA, Hu K, Evoniuk H. et al. Impact of the human circadian system, exercise, and their interaction on cardiovascular function. Proc Natl Acad Sci USA 2010; 107: 20541-20546.
• 19 Scheer FA, Michelson AD, Frelinger AL. 3rd, et al. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One 2011; 06: e24549.
• 20 Kozinski M, Bielis L, Wisniewska-Szmyt J. et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22: 579-587.
• 21 Bonten TN, Saris A, van Oostrom MJ. et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost 2014; 112: 1209-1218.
• 22 Authors/Task Force m. Windecker S, Kolh P. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619.
• 23 Aradi D, Kirtane A, Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015 Epub ahead of print.
• 24 Henry P, Vermillet A, Boval B. et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344.
• 25 Perneby C, Wallen NH, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
• 26 Lordkipanidze M, Pharand C, Schampaert E. et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011; 150: 39-44.
• 27 Wurtz M, Hvas AM, Jensen LO. et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014; 175: 274-279.
• 28 Rocca B, Santilli F, Pitocco D. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-1230.
• 29 Christensen KH, Grove EL, Wurtz M. et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets 2015; 26: 230-235.
• 30 Kriszbacher I, Ajtay Z, Koppan M. et al. Can the time of taking aspirin influence the frequency of cardiovascular events?. Am J Cardiol 2005; 96: 608-610.
• 31 Investigators C-O, Mehta SR, Bassand JP. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
• 32 Beres BJ, Toth-Zsamboki E, Vargova K. et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual anti-platelet therapy. Thromb Haemost 2008; 100: 829-838.
• 33 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 34 Steg PG, Harrington RA, Emanuelsson H. et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128: 1055-1065.
• 35 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.